Literature DB >> 31930047

Relevance of arm somatic copy number alterations for oncologic outcomes and tumor immune microenvironment in clear cell renal cell carcinoma.

Ying Xiong1, Yu Qi1, Qi Bai1, Yu Xia1, Li Liu1, Jianming Guo1.   

Abstract

BACKGROUND: Prognostic value of arm somatic copy number alterations (SCNAs) in clear cell renal cell carcinoma (ccRCC) have not been systematically evaluated in a large cohort. Its association with tumor microenvironment remained unknown.
METHODS: We retrospectively correlated arm SCNAs with OS and recurrence free survival (RFS) in a cohort of 524 ccRCC patients. The prognostic landscape of arm SCNA was depicted by bubble heatmap. Associations between arm SCNAs and tumor microenvironment were evaluated by CIBERSORT and Gene Set Enrichment Analysis (GSEA).
RESULTS: We found that amplifications of 1p, 3p and loss of 4p, 4q, 5p, 5q, 11p, 11q, 11q, 13q, 19p were independent adverse risk factor for OS, while amplification of 1q and deletions of 4p, 4q, 9p, 9q associated with worse RFS. Loss of 4q were independent adverse risk factor for OS (P=0.012, HR =1.614) and RFS (P=0.001, HR =2.005). It could identify a subset of early stage ccRCC patients with high risk of death and recurrence. CXCL9, CXCL10, CXCL11 mRNA level and CD8+ T cell infiltration were downregulated in ccRCC with 4q deletion. Patients with high arm SCNA level had shorter OS (P=0.005) and RFS (P=0.001). Markers, immune cells and pathways referring to immune suppression were elevated in tumors with high arm SCNA level.
CONCLUSIONS: In conclusion, loss of 4q was an independent adverse risk factor for OS and RFS in ccRCC patients and contributed to cytotoxic cell exclusion via downregulation of CXCL9, CXCL10 and CXCL11. Patients with higher arm SCNAs had worse survival and a more immunosuppressive tumor microenvironment. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Somatic copy number alterations; clear cell renal cell carcinoma (ccRCC); immune microenvironment; prognosis

Year:  2019        PMID: 31930047      PMCID: PMC6944545          DOI: 10.21037/atm.2019.10.54

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  27 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.

Authors:  Jeffrey La Rochelle; Tobias Klatte; Aditi Dastane; Nagesh Rao; David Seligson; Jonathan Said; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie Belldegrun; Allan J Pantuck
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

3.  Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma.

Authors:  Hangcheng Fu; Yu Zhu; Yiwei Wang; Zheng Liu; Junyu Zhang; Zewei Wang; Huyang Xie; Bo Dai; Jiejie Xu; Dingwei Ye
Journal:  Ann Surg Oncol       Date:  2016-11-28       Impact factor: 5.344

Review 4.  The Basis of Oncoimmunology.

Authors:  A Karolina Palucka; Lisa M Coussens
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

Review 5.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

6.  Prognostic implications of cytogenetic findings in kidney cancer.

Authors:  P Elfving; N Mandahl; R Lundgren; J Limon; E Bak-Jensen; M Fernö; H Olsson; F Mitelman
Journal:  Br J Urol       Date:  1997-11

7.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

8.  Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.

Authors:  Timothy Ito; Jianming Pei; Essel Dulaimi; Craig Menges; Philip H Abbosh; Marc C Smaldone; David Y T Chen; Richard E Greenberg; Alexander Kutikov; Rosalia Viterbo; Robert G Uzzo; Joseph R Testa
Journal:  J Urol       Date:  2015-11-18       Impact factor: 7.450

9.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

10.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

View more
  4 in total

1.  Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma.

Authors:  Chuanjie Zhang; Feng Qi; Yuxiao Zheng; Xin Xia; Xiao Li; Xinwei Wang
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

Review 2.  Hypoxia and the phenomenon of immune exclusion.

Authors:  Violena Pietrobon; Francesco M Marincola
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

3.  Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.

Authors:  Yoshie Yoshikawa; Yusuke Yamada; Mitsuru Emi; Lilit Atanesyan; Jan Smout; Karel de Groot; Suvi Savola; Yukako Nakanishi-Shinkai; Akihiro Kanematsu; Michio Nojima; Masaki Ohmuraya; Tomoko Hashimoto-Tamaoki; Shingo Yamamoto
Journal:  Cancer Sci       Date:  2021-11-03       Impact factor: 6.716

4.  The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma.

Authors:  Monika Gudowska-Sawczuk; Jacek Kudelski; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-11-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.